Evgen Pharma Stock Price, News & Analysis (LON:EVG)

GBX 15.50 -0.75 (-4.62 %)
(As of 01/17/2018 03:24 AM ET)
Previous CloseGBX 16.25
Today's RangeGBX 15 - GBX 16.10
52-Week RangeGBX 12.52 - GBX 30.25
Volume296,479 shs
Average Volume94,642 shs
Market Capitalization£14.87 million
P/E Ratio-387.50
Dividend YieldN/A
BetaN/A

About Evgen Pharma (LON:EVG)

Evgen Pharma logoEvgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.

Receive EVG News and Ratings via Email

Sign-up to receive the latest news and ratings for EVG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolLON:EVG
CUSIPN/A
Phone+44-151-7053532

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-387.5
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.04)
Net IncomeN/A
Net MarginsN/A
Return on Equity-97.50%
Return on Assets-86.51%

Miscellaneous

EmployeesN/A
Outstanding Shares74,110,000

Evgen Pharma (LON:EVG) Frequently Asked Questions

What is Evgen Pharma's stock symbol?

Evgen Pharma trades on the London Stock Exchange (LON) under the ticker symbol "EVG."

Where is Evgen Pharma's stock going? Where will Evgen Pharma's stock price be in 2018?

2 analysts have issued 12-month price objectives for Evgen Pharma's stock. Their predictions range from GBX 97 to GBX 97. On average, they anticipate Evgen Pharma's share price to reach GBX 97 in the next twelve months. View Analyst Ratings for Evgen Pharma.

Who are some of Evgen Pharma's key competitors?

Who are Evgen Pharma's key executives?

Evgen Pharma's management team includes the folowing people:

  • Barry Clare, Executive Chairman of the Board (Age 62)
  • Stephen Joseph Franklin, Chief Executive Officer, Executive Director (Age 47)
  • Richard Moulson, Chief Financial Officer, Director
  • Hamina J. Patel, Chief Medical Officer
  • Alan Barge, Non-Executive Director (Age 58)
  • Marc F. D'Abbadie Ph.D., Non-Executive Director
  • Sue Foden Ph.D., Non-Executive Director (Age 62)

How do I buy Evgen Pharma stock?

Shares of Evgen Pharma and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Evgen Pharma's stock price today?

One share of Evgen Pharma stock can currently be purchased for approximately GBX 15.50.

How big of a company is Evgen Pharma?

Evgen Pharma has a market capitalization of £14.87 million.

How can I contact Evgen Pharma?

Evgen Pharma's mailing address is The Colony 146 Brownlow Hill, Altrincham Road, WILMSLOW, SK9 4LY, United Kingdom. The company can be reached via phone at +44-151-7053532.


MarketBeat Community Rating for Evgen Pharma (EVG)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about Evgen Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Evgen Pharma (LON:EVG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 97GBX 97GBX 97GBX 97

Evgen Pharma (LON:EVG) Consensus Price Target History

Price Target History for Evgen Pharma (LON:EVG)

Evgen Pharma (LON:EVG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/15/2018Northland SecuritiesReiterated RatingBuyView Rating Details
12/15/2017Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Earnings History for Evgen Pharma (LON:EVG)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Evgen Pharma (LON:EVG) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Evgen Pharma (LON:EVG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Evgen Pharma (LON EVG) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Evgen Pharma (LON:EVG)

Evgen Pharma (LON EVG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/18/2016Clare,BarryInsiderBuy40,000GBX 22£8,800
(Data available from 1/1/2013 forward)

Headlines

Evgen Pharma (LON EVG) News Headlines

Source:
DateHeadline
Northland Securities Reaffirms Buy Rating for Evgen Pharma (EVG)Northland Securities Reaffirms Buy Rating for Evgen Pharma (EVG)
www.americanbankingnews.com - January 15 at 6:40 PM
Seneca Partners Almost Doubles Evgen Pharma Stake To 7.4% (ALLISS)Seneca Partners Almost Doubles Evgen Pharma Stake To 7.4% (ALLISS)
www.morningstar.co.uk - January 12 at 10:07 AM
Two Investment Funds Build Stakes In Evgen Pharma (ALLISS)Two Investment Funds Build Stakes In Evgen Pharma (ALLISS)
www.morningstar.co.uk - January 5 at 10:13 AM
Evgen Pharma (EVG) Receives Speculative Buy Rating from Beaufort SecuritiesEvgen Pharma (EVG) Receives Speculative Buy Rating from Beaufort Securities
www.americanbankingnews.com - December 16 at 10:40 AM
Evgen Pharma Shares Drop On Discounted Placing, Loss Stays Flat (ALLISS)Evgen Pharma Shares Drop On Discounted Placing, Loss Stays Flat (ALLISS)
www.morningstar.co.uk - December 8 at 4:44 PM
Evgen Pharma PLC (EVG) Earns Speculative Buy Rating from Beaufort SecuritiesEvgen Pharma PLC (EVG) Earns Speculative Buy Rating from Beaufort Securities
www.americanbankingnews.com - October 8 at 9:24 AM
Evgen Pharma Progressing With Clinical Trials For Sulforaphane DrugEvgen Pharma Progressing With Clinical Trials For Sulforaphane Drug
www.morningstar.co.uk - July 26 at 7:01 PM
Evgen Pharma Loss Widens As SFX-01 Clinical Trials ProgressEvgen Pharma Loss Widens As SFX-01 Clinical Trials Progress
www.morningstar.co.uk - June 13 at 11:39 AM
Evgen Pharma SFX-01 Trials Progressing With No Safety Issues To DateEvgen Pharma SFX-01 Trials Progressing With No Safety Issues To Date
www.morningstar.co.uk - June 2 at 11:24 PM
CFO Moves: Novae Group, Evgen PharmaCFO Moves: Novae Group, Evgen Pharma
blogs.wsj.com - January 18 at 3:49 AM
Evgen Pharma Eyeing Third Clinical Programme After First Half ProgressEvgen Pharma Eyeing Third Clinical Programme After First Half Progress
www.morningstar.co.uk - December 5 at 5:44 PM
Half Year 2017 Evgen Pharma PLC Earnings Release - Time Not SuppliedHalf Year 2017 Evgen Pharma PLC Earnings Release - Time Not Supplied
biz.yahoo.com - December 5 at 11:44 AM
Evgen Pharma Shares Rise On Back Of Teaser For SFX-01 ResultsEvgen Pharma Shares Rise On Back Of Teaser For SFX-01 Results
www.morningstar.co.uk - September 8 at 4:50 PM
BRIEF-Evgen Pharma granted orphan drug designation for stabilised sulforaphaneBRIEF-Evgen Pharma granted orphan drug designation for stabilised sulforaphane
www.reuters.com - August 24 at 4:51 PM
Full Year 2016 Evgen Pharma PLC Earnings Release - Time Not SuppliedFull Year 2016 Evgen Pharma PLC Earnings Release - Time Not Supplied
biz.yahoo.com - May 31 at 7:07 AM
Osteoarthritis Pipeline Market H1 2016 Global Review ReportOsteoarthritis Pipeline Market H1 2016 Global Review Report
www.thestreet.com - April 28 at 10:18 AM
CORRECT: DIRECTOR DEALINGS: Evgen Pharma Directors Buy 136,000 SharesCORRECT: DIRECTOR DEALINGS: Evgen Pharma Directors Buy 136,000 Shares
www.morningstar.co.uk - January 20 at 7:26 AM
DIRECTOR DEALINGS: Evgen Pharma Directors Bought 136,000 SharesDIRECTOR DEALINGS: Evgen Pharma Directors Bought 136,000 Shares
www.morningstar.co.uk - January 19 at 7:36 AM

SEC Filings

Evgen Pharma (LON:EVG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Evgen Pharma (LON EVG) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.